Oral infections caused by yeasts in patients with head and neck cancer undergoing radiotherapy. Identification of the yeasts and evaluation of their antifungal susceptibility

Journal de Mycologie Medicale

Volumn 22, Issue 4, 2012, Pages 348-353

  Bulacio, L ^a   Paz, M ^a   Ramadan S ^a   Ramos, L ^a   Pairoba, C ^a   Sortino, M ^a   Escovich, L ^a   Lopez C ^a  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Antifungal susceptibility; Cancer treatment; Head and neck cancer; Oral candidiasis; Radiotherapy

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FUNGAL DETECTION; FUNGAL STRAIN; FUNGAL STRUCTURES; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOUTH INFECTION; NONHUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; SACCHAROMYCES CEREVISIAE; SPECIES DIFFERENTIATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; HEAD AND NECK NEOPLASMS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; NAPHTHALENES; NYSTATIN; OPPORTUNISTIC INFECTIONS; SACCHAROMYCES CEREVISIAE; SPECIES SPECIFICITY; TRIAZOLES;

CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; ISSATCHENKIA ORIENTALIS; SACCHAROMYCES CEREVISIAE;

EID: 84870549237     PISSN: 11565233     EISSN: 17730449     Source Type: Journal    
DOI: 10.1016/j.mycmed.2012.08.002     Document Type: Article

References (29)

1. Akpan A., Morgan R. Oral Candidiasis (review). Post Grad Med J 2002, 78:455-459.
2. Burn A.K., Fothergill A.W., Kirckpatrick W.R., Coco B.J., Patterson T.F., McCarthy D.I., et al. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients. J Clin Microbiol 2004, 42:5846-5848.
3. Cantón E., Pemán J., Gobernado M., Viudes A., Espinel-Ingroff A. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 2005, 49:1593-1596.
4. Clinical Laboratory Standards Institute (CLSI) Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline-Document M44-A 2004, Wayne, Pennsylvania.
5. Clinical Laboratory Standars Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard CLSI document M27 A3 2008, Wayne, Pennsylvania. Third Edition.
6. Cugno C., Cesaro S. Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep 2012, 4:30-33.
7. Diogo H.C., Melhem M., Sarpieri A., Pires M.C. Evaluation of the disk-diffusion method to determine the in vitro efficacy of terbinafine against subcutaneous and superficial mycoses agents. An Bras Dermatol 2010, 85:324-330.
8. Edmond M.B., Wallace S.E., Mc Clish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-years analysis. Clin Infect Dis 1999, 29:239-244.
9. Keung Leung W., Dassanayake R., Yau J., Jian Jin L., Cheong Yam W., Samaranayake L. Oral colonization, Phenotypic and genotypic profiles of Candida species in irradiated, dentate, xerostomic nasopharingeal carcinoma survivors. J Clin Microbiol 2000, 38:2219-2226.
10. Lalla R.V., Brennan M.T., Schubert M.M. Oral complications of cancer therapy. Pharmacology and therapeutics for dentistry 2011, 782-798. Mo: Mosby Elsevier, St. Louis. 6th ed. J.A. Yagiela, F.J. Dowd, B.S. Johnson, A. Mariotti, E.A. Neidle (Eds.).
11. Lalla R.V., Latortue M.C., Hong C.H., Ariyawardana A., D'Amato-Palumbo S., Fischer D.J., et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 2010, 18:985-992.
12. Li H., Qiao J., Wan Z., Zhang J. In vitro interaction of Itraconazole with amphotericin B, caspofungin, and terbinafine against clinical isolates of Trichosporon asahii. Mycopathologia 2011, 171:345-348.
13. Mann P.A., McNicholas P.M., Chau A.S., Patel R., Mendrick C., Ullmann A.J., et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009, 53:5026-5034.
14. Marcos-Arias C., Eraso E., Madariaga L., Carrillo-Muñoz A.J., Quindós G. In vitro activities of new triazole antifungal agents, posaconazole and voriconazole against oral Candida isolates from patients suffering from denture stomatitis. Mycopathologia 2012, 173:35-46.
15. Naglik J.R., Challacombe S.J., Hube B. Candida albicans secreted aspartil proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003, 67:400-428.
16. Nomanbhoy F., Steele C., Yano J., Fidel P.L.J Jr. Vaginal and oral epithelial cell anti-Candida activity. Infect Immun 2002, 70:7081-7088.
17. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
18. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998, 31:327-332.
19. Porte L., León P., Gárate C., Guzmán A.M., Labarca J., García P. Susceptibilidad a azoles y anfotericina B de aislados de Candida spp. Experiencia de una red de salud universitaria entre 2004 y 2010. Rev Chil Infect 2012, 29:149-155.
20. Redding S., Kirkpatrick W., Saville S., Coco B., White W., Fothergill A., et al. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol 2003, 41:619-622.
21. Reddinng S.W., Zellars R.C., Kirckpatrick W.R., McAtee R.K., Caceres M.A., Fothergill A.W., et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 1999, 37:3896-3900.
22. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida albicans yeasts. Curr Drug Targets 2006, 7:495-504.
23. Ruhnke M., Eigler A., Tennagen I., Geiseler B., Angelman E., Trautmann M. Emergende of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994, 32:2092-2098.
24. Saghrouni F., Bougmiza I., Ben Abdeljelil J., Yacoub A., Khammari I., Fathallah A., et al. Epidemiological trends in invasive candidiasis: results from a 15 year study in Sousse region, Tunisia. J Mycol Med 2011, 21:123-129.
25. Silva J.A. Las complicaciones producidas por el tratamiento con radiaciones ionizantes de los Carcinomas de la Cavidad Bucal. Rev Cubana Estomatol 1982, 19:58-63.
26. Ueta E., Tanida T., Yoneda K., Yamamoto T., Osaki T. Increase of Candida cell virulence by anticancer drugs and irradiation. Oral Microbiol Immunol 2001, 16:243-249.
27. Umazume M., Ueta E., Osaki T. Reduced inhibition of Candida albicans adhesion by saliva from patients receiving oral cancer therapy. J Clin Microbiol 1995, 33:432-439.
28. Weig M., Müller F.M.C. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2001, 45:966-968.
29. Zomorodian K., Rahimi M.J., Pakshir K., Motamedi M., Ghiasi M.R., Rezashah H. Determination of antifungal susceptibility patterns among the clinical isolates of Candida species. J Glob Infect Dis 2011, 3:357-360.